CSF3R

Granulocyte colony-stimulating factor receptor

67 patent compounds predicted against CSF3R, 24 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18551002	0.51	2/20
SCHEMBL2207505	0.48	1/20
SCHEMBL2208586	0.46	1/20
SCHEMBL29818702	0.46	1/20
SCHEMBL11341527	0.45	1/20
SCHEMBL11341529	0.45	1/20
SCHEMBL28032739	0.45	1/20
Trifluoroacetic Acid (SCHEMBL946939)	0.44	1/20
SCHEMBL4888126	0.44	1/20
SCHEMBL611960	0.43	1/20
SCHEMBL26206374	0.43	1/20
SCHEMBL27763796	0.43	1/20
SCHEMBL4896415	0.43	1/20
Hexanoate (SCHEMBL29036122)	0.43	1/20
SCHEMBL14018571	0.42	1/20
SCHEMBL3964539	0.42	1/20
SCHEMBL6179341	0.42	1/20
SCHEMBL4282160	0.42	1/20
SCHEMBL3882491	0.41	1/20
SCHEMBL15805902	0.41	1/20

Germline variants in CSF3R on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CSF3R gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CSF3R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bone Marrow Progenitor Cell Mobilization in Diabetes	PHASE4	COMPLETED
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality	PHASE3	COMPLETED
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions	PHASE3	RECRUITING
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)	PHASE3	ACTIVE_NOT_RECRUITING
Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.	PHASE3	ACTIVE_NOT_RECRUITING
Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	PHASE2	COMPLETED
The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy	PHASE2	COMPLETED
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis	PHASE2	COMPLETED
GM-CSF as Adjuvant Therapy of Melanoma	PHASE2	COMPLETED
CSL324 in COVID-19	PHASE2	WITHDRAWN
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma	PHASE2	COMPLETED
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer	PHASE2	WITHDRAWN
Niraparib + Dostarlimab + RT in Pancreatic Cancer	PHASE2	COMPLETED
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer	PHASE1/PHASE2	COMPLETED
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas	PHASE2	COMPLETED
BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)	PHASE2	COMPLETED
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma	PHASE2	COMPLETED
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma	PHASE1	WITHDRAWN
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-up	PHASE1	COMPLETED
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Clinical Trial Protocol for the Combined Use of VAG in the Treatment of ND-AML	nan	RECRUITING
Assessment of Salivary GM-CSF, MIP, and IL-1β Levels in Subjects With Varying Periodontal Conditions	nan	RECRUITING
Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSF3R binder may also engage these)

Protein	Name	Similarity
P40223	—	0.994	P40223 →
MPL	Thrombopoietin receptor	0.994	landscape →
Q08351	—	0.992	Q08351 →
P22273	—	0.991	P22273 →
Q6UWB1	—	0.989	Q6UWB1 →
P42701	—	0.987	P42701 →
P22272	—	0.986	P22272 →
O70394	—	0.984	O70394 →
Q8MJS1	—	0.984	Q8MJS1 →
Q9BEG2	—	0.984	Q9BEG2 →
Q60837	—	0.982	Q60837 →
P14753	—	0.980	P14753 →
O70540	—	0.979	O70540 →
P26954	—	0.979	P26954 →
P0DP72	—	0.979	P0DP72 →
Q9HC73	—	0.978	Q9HC73 →
P34902	—	0.978	P34902 →
P31785	—	0.978	P31785 →
Q61826	—	0.978	Q61826 →
P32927	—	0.977	P32927 →
Q99665	—	0.977	Q99665 →
Q95118	—	0.977	Q95118 →
A0A140LHF2	—	0.976	A0A140LHF2 →
Q07303	—	0.976	Q07303 →
EPOR	Erythropoietin receptor	0.976	landscape →
Q96AP7	—	0.976	Q96AP7 →
Q9MYZ9	—	0.976	Q9MYZ9 →
Q7L513	—	0.976	Q7L513 →
Q80ZE3	—	0.976	Q80ZE3 →
Q8K4C2	—	0.976	Q8K4C2 →